Cardiovascular risk-benefit ratio of thiazolidinediones
Lipska K, Inzucchi S. Cardiovascular risk-benefit ratio of thiazolidinediones. Current Cardiovascular Risk Reports 2008, 3: 42-50. DOI: 10.1007/s12170-009-0008-9.Peer-Reviewed Original ResearchRisk-benefit ratioType 2 diabetes mellitusActual cardiovascular outcomesSurrogates of atherosclerosisDifferential clinical effectsInsulin-sensitizing thiazolidinedionesEffective antihyperglycemic agentCardiovascular eventsCardiovascular outcomesCardiovascular implicationsBlood pressureDiabetes mellitusEndothelial functionHeart failureClinical effectsInsulin resistanceAntihyperglycemic agentsFluid retentionLipid profileThiazolidinedionesPatientsAvailable membersBeneficial impactMellitusT2DM
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply